NOT AN OFFER TO INVEST. RED HERRING DISCLOSURE AVAILABLE ON REQUEST. PROFESSIONAL INVESTORS ONLY.

January 2023

BIRD FLU REPORT. 19 JAN 2023. EUROSURVEILLANCE. TRANSMISSION IN MINK. Highly pathogenic avian influenza A(H5N1) virus infection in farmed minks, Spain, October 2022.

By |January 20, 2023|Categories: Blog Posts|

BIRD FLU REPORT. 19 JANUARY 2023. Remember the MINK [...]

Read More
Comments Off on BIRD FLU REPORT. 19 JAN 2023. EUROSURVEILLANCE. TRANSMISSION IN MINK. Highly pathogenic avian influenza A(H5N1) virus infection in farmed minks, Spain, October 2022.

PERSPECTIVE. CONTAGION (2011) TRAILER (2:28). “Someone doesn’t have to weaponise the bird flu. The birds are doing that.”

By |January 19, 2023|Categories: Blog Posts|

CONTAGION (2011) TRAILER (2:28). "Someone doesn't have to weaponise the [...]

Read More
Comments Off on PERSPECTIVE. CONTAGION (2011) TRAILER (2:28). “Someone doesn’t have to weaponise the bird flu. The birds are doing that.”

PERSPECTIVE. EXTREME COST OF COVID-19: $28+ TRILLION LOST. 22+ MILLION LIVES LOST. 65+ MILLION DISABLED by LONG COVID.

By |January 18, 2023|Categories: Blog Posts|

The Extreme Cost of the COVID-19 Pandemic (with references) [...]

Read More
Comments Off on PERSPECTIVE. EXTREME COST OF COVID-19: $28+ TRILLION LOST. 22+ MILLION LIVES LOST. 65+ MILLION DISABLED by LONG COVID.

NATURE REVIEW MICROBIOLOGY. Long COVID: major findings, mechanisms and recommendations. 13 JAN 2023. “At least 65 million individuals worldwide are estimated to have long COVID, with cases increasing daily.”

By |January 15, 2023|Categories: Blog Posts|

NATURE REVIEW MICROBIOLOGY. Long COVID: major findings, mechanisms and [...]

Read More
Comments Off on NATURE REVIEW MICROBIOLOGY. Long COVID: major findings, mechanisms and recommendations. 13 JAN 2023. “At least 65 million individuals worldwide are estimated to have long COVID, with cases increasing daily.”

NEWS. ECDC. 9 Jan 2023. Update on SARS-CoV-2 variants: ECDC assessment of the XBB.1.5 sub-lineage

By |January 13, 2023|Categories: Blog Posts|

Source: https://gisaid.org/hcov-19-analysis-update/ NEWS. ECDC. 9 Jan 2023. Update on [...]

Read More
Comments Off on NEWS. ECDC. 9 Jan 2023. Update on SARS-CoV-2 variants: ECDC assessment of the XBB.1.5 sub-lineage

GROUND TRUTHS. REPORT. DR ERIC TOPOL. JAN 12. The bivalent vaccine booster outperforms. A review of the cumulative body of evidence.

By |January 12, 2023|Categories: Blog Posts|

GROUND TRUTHS by ERIC TOPOL. The bivalent vaccine booster outperforms. [...]

Read More
Comments Off on GROUND TRUTHS. REPORT. DR ERIC TOPOL. JAN 12. The bivalent vaccine booster outperforms. A review of the cumulative body of evidence.
By |2023-02-09T13:57:54+00:00February 9, 2023|Uncategorized|Comments Off on
Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.2023-02-03T11:00:00+00:00

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax Abstract2022-08-31T11:50:39+00:00

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.

Copyright 2021 | Normax Biomed Limited | First Floor, Penrose 1, Penrose Dock, Cork, Ireland | T23 KW81 | Company Number 669518

error: Content is protected !!
Go to Top